These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24600724)

  • 1. Meningococcal vaccine A,C,W135,Y: conjugated to tetanus toxoid.
    Prescrire Int; 2013 Dec; 22(144):285-8. PubMed ID: 24600724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).
    Croxtall JD; Dhillon S
    Drugs; 2012 Dec; 72(18):2407-30. PubMed ID: 23231026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.
    Knuf M; Kieninger-Baum D; Habermehl P; Muttonen P; Maurer H; Vink P; Poolman J; Boutriau D
    Vaccine; 2010 Jan; 28(3):744-53. PubMed ID: 19887137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
    El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
    Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age.
    Baxter R; Baine Y; Ensor K; Bianco V; Friedland LR; Miller JM
    Pediatr Infect Dis J; 2011 Mar; 30(3):e41-8. PubMed ID: 21200360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children.
    Knuf M; Pantazi-Chatzikonstantinou A; Pfletschinger U; Tichmann-Schumann I; Maurer H; Maurer L; Fischbach T; Zinke H; Pankow-Culot H; Papaevangelou V; Bianco V; Van der Wielen M; Miller JM
    Vaccine; 2011 Jun; 29(25):4264-73. PubMed ID: 21420417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: an open, randomised, controlled trial.
    Østergaard L; Silfverdal SA; Berglund J; Flodmark CE; West C; Bianco V; Baine Y; Miller JM
    Vaccine; 2012 Jan; 30(4):774-83. PubMed ID: 22107850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile.
    Memish ZA; Dbaibo G; Montellano M; Verghese VP; Jain H; Dubey AP; Bianco V; Van der Wielen M; Gatchalian S; Miller JM
    Pediatr Infect Dis J; 2011 Apr; 30(4):e56-62. PubMed ID: 21278617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults.
    Deeks ED
    BioDrugs; 2010 Oct; 24(5):287-97. PubMed ID: 20795751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial.
    Vesikari T; Karvonen A; Bianco V; Van der Wielen M; Miller J
    Vaccine; 2011 Jun; 29(25):4274-84. PubMed ID: 21443965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers.
    Bryant KA; Marshall GS
    Expert Rev Vaccines; 2011 Jul; 10(7):941-50. PubMed ID: 21806393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence.
    Findlow J; Knuf M
    Future Microbiol; 2019 May; 14():563-580. PubMed ID: 31091978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix
    Dhillon S; Pace D
    Drugs; 2017 Nov; 77(17):1881-1896. PubMed ID: 29094312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review.
    Ghanem S; Hassan S; Saad R; Dbaibo GS
    Expert Opin Biol Ther; 2013 Aug; 13(8):1197-205. PubMed ID: 23815506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.
    Findlow H; Borrow R
    Adv Ther; 2013 May; 30(5):431-58. PubMed ID: 23712402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.
    Stamboulian D; Lopardo G; Lopez P; Cortes-Barbosa C; Valencia A; Bedell L; Karsten A; Dull PM
    Int J Infect Dis; 2010 Oct; 14(10):e868-75. PubMed ID: 20655261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.